Key result
Prior oral anticoagulation shows no link to worse severity or 12-month outcomes in subarachnoid hemorrhage.
Why the study?
DOACs are replacing VKAs for stroke and venous thromboembolism prevention, but the effect of prior DOAC or VKA treatment in aneurysmal subarachnoid hemorrhage was unclear.
Does prior treatment with DOACs or VKAs worsen radiological hemorrhage severity or clinical outcomes in patients with aneurysmal subarachnoid hemorrhage?
Case-Control (n=964)
Yes
Does prior treatment with DOACs or VKAs worsen radiological hemorrhage severity or clinical outcomes in patients with aneurysmal subarachnoid hemorrhage?
Prior treatment with DOACs or VKAs does not appear to independently increase radiological bleeding severity or worsen long-term clinical outcomes in hospitalized patients with aneurysmal subarachnoid hemorrhage.
Answers are grounded in this paper and cite their sources.
Anticoagulant pretreatment was not linked to worse aneurysmal SAH outcomes; hypothesis-generating and should not yet change practice.
Objective—Direct oral anticoagulants (DOAC) are replacing vitamin K antagonists (VKA) for the prevention of ischemic stroke and venous thromboembolism. We set out to assess the effect of prior treatment with DOAC and VKA in patients with aneurysmal subarachnoid hemorrhage (SAH). Methods—Consecutive SAH patients treated at two (Aachen, Germany and Helsinki, Finland) university hospitals were considered for inclusion. To assess the association between anticoagulant treatments on SAH severity measure by modified Fisher grading (mFisher) and outcome as measured by the Glasgow outcome scale (GOS, 6 months), DOAC- and VKA-treated patients were compared against age- and sex-matched SAH controls without anticoagulants. Results—During the inclusion timeframes, 964 SAH patients were treated in both centers. At the time point of aneurysm rupture, nine patients (0.93%) were on DOAC treatment, and 15 (1.6%) patients were on VKA. These were matched to 34 and 55 SAH age- and sex-matched controls, re-spectively. Overall, 55.6% of DOAC-treated patients suffered poor-grade (WFNS4–5) SAH compared to 38.2% among their respective controls (p = 0.35); 53.3% of patients on VKA suffered poor-grade SAH compared to 36.4% in their respective controls (p = 0.23). Neither treatment with DOAC (aOR 2.70, 95%CI 0.30 to 24.23; p = 0.38), nor VKA (aOR 2.78, 95%CI 0.63 to 12.23; p = 0.18) were inde-pendently associated with unfavorable outcome (GOS1–3) after 12 months. Conclusions—Iatrogenic coagulopathy caused by DOAC or VKA was not associated with more severe radiological or clinical subarachnoid hemorrhage or worse clinical outcome in hospitalized SAH patients.
No takes yet. Share an insight, caveat, or question.
Veldeman et al. (2023) conducted a case-control in Aneurysmal subarachnoid hemorrhage (n=964). Direct oral anticoagulants (DOAC) vs. Age- and sex-matched SAH controls without anticoagulants was evaluated on Unfavorable outcome (Glasgow Outcome Scale 1-3) after 12 months (aOR 2.70, 95% CI 0.30 to 24.23, p=0.38). Prior treatment with DOACs or VKAs was not independently associated with more severe radiological or clinical subarachnoid hemorrhage, nor with worse clinical outcome at 12 months compared to matched controls.
Synapse has enriched 10 related papers. Consider them for comparative context: